Liquid biopsy diagnosis platform Freenome has raised $65m in a series A funding round led by US venture capital firm Andreessen Horowitz. The 25-person company has said that its tests outperform current screening options for breast, prostate, colorectal and lung cancers. “People are going to be able to get the results they need at home without having to go into an office or pay hundreds of dollars out of pocket,” says Dr David King, chief executive of However, no liquid biopsy firm has yet been able to pinpoint where a tumour is growing or what the prognosis is. Freenome plans to use its funding to start clinical trials with the help of 25 research partners.
Liquid biopsy diagnosis platform Freenome has raised $65m in a series A funding round led by US venture capital firm Andreessen Horowitz. The 25-person company has said that its tests outperform current screening options for breast, prostate, colorectal and lung cancers. The firm's technology uses a patient's DNA to diagnose cancer, rather than relying on traditional tissue biopsies. However, no liquid biopsy firm has yet been able to pinpoint where a tumour is growing or what the prognosis is. Freenome plans to use its funding to start clinical trials with the help of 25 research partners.